T-Control® Safety for Cytostatics Management

NANot yet recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

February 28, 2027

Conditions
Non-muscle-invasive Bladder Cancer
Interventions
DEVICE

T-Control® (experimental)

Patients will receive intravesical therapy (1-2 hours) through T-Control®, a new Foley-type silicone catheter with an integrated fluid-control valve into the catheter's distal end, which has three positions.

DEVICE

Folysil® (control)

Patients will receive intravesical therapy (1-2 hours) through Folysil® Silicone catheter (Coloplast), the usual clinical practice in the participating center.

All Listed Sponsors
lead

Rethink Medical SL

INDUSTRY